Hair loss treatment used by millions linked to suicide risk: ‘Evidence is no longer anecdotal’

New research indicates Finasteride (Propecia), a widely used hair loss treatment, is significantly linked to increased risks of mood disorders and suicidal thoughts, prompting calls for its marketing suspension for cosmetic use and a full safety reassessment. This development poses substantial regulatory and product liability risks for manufacturers, including Merck, potentially impacting their market position in the multi-billion dollar hair loss treatment sector. Concurrently, a new study suggests combining minoxidil with stevioside could enhance its efficacy, presenting a potential market opportunity for alternative, safer hair loss solutions.

Analysis

New research led by Dr. Mayer Brezis strongly links Finasteride (Propecia) to increased risks of mood disorders and suicidal thoughts, moving beyond anecdotal evidence to consistent patterns across diverse populations. This finding highlights significant historical regulatory oversight, with alleged internal FDA recommendations for label warnings in 2010 being rejected, and a "systemic failure of pharmacovigilance" leading to potential underreporting of thousands of suicides globally.

The revelations pose substantial product liability and reputational risks for Merck (MRK), the original manufacturer, which is partly blamed for allegedly skipping basic safety research. Dr. Brezis advocates for an immediate suspension of finasteride marketing for cosmetic use and a full safety reassessment, alongside stricter post-approval study mandates from the FDA.

Concurrently, a new study presents a potential market opportunity for safer hair loss solutions, demonstrating that combining minoxidil with stevioside significantly enhances its skin absorption and efficacy. This innovation could address the substantial market for androgenetic alopecia, affecting 80 million in the US alone, offering a more effective and potentially safer alternative to Finasteride.

Key Decisions for Investors

• Investors holding MRK should assess the potential for increased legal liabilities and reputational damage stemming from the Finasteride revelations, monitoring for class-action lawsuits or regulatory actions.
• Evaluate the broader pharmaceutical sector for companies with similar long-standing drugs that could face renewed scrutiny over historical safety data and pharmacovigilance practices.
• Consider investment opportunities in companies developing or commercializing alternative, safer hair loss treatments, particularly those leveraging enhanced minoxidil formulations, given the significant market demand and Finasteride's newly highlighted risks.